All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Alexandra M. Stevens and colleagues from the Baylor College of Medicine, Houston, Texas, investigated the role of Interleukin-6 (IL-6) levels in the Bone Marrow (BM) microenvironment and its association with the clinical response to cytotoxic chemotherapy in pediatric Acute Myeloid Leukemia (AML) patients. The results of the study were published in Blood Advances on 8th August 2017.
BM samples from pediatric AML patients (AML cohort; n = 45) who were treated with chemotherapy at the Texas Children’s Cancer and Hematology Center between 2007–2016 and healthy sibling donors (NBM cohort; n = 7) were analyzed for their IL-6 levels. The median levels of IL-6 were significantly higher in AML patients (11.79 pg/ml) compared to the healthy controls (1.7 pg/ml). Patients were grouped into high (n = 21) and low (n = 24) levels of IL-6 using a cut-point of 12 pg/ml.
In summary, pediatric AML patients with increased levels of IL-6 have poorer EFS, which may be as a result of IL-6-induced chemoresistance.
The authors concluded their study by noting that “IL-6 levels at diagnosis could be used to help identify children at high risk of relapse, particularly those who are otherwise classified as low risk by current algorithms”. They further proposed that targeting the “IL-6 signaling pathway can potentially eradicate chemoresistant LSCs and prevent relapse” in pediatric AML patients.
The tumor microenvironment can protect cancer cells from conventional anticancer therapies. Thus, targeting these protective mechanisms could eradicate therapy-resistant cancer cells and improve outcomes. Interleukin-6 (IL-6) provides extrinsic protection for several solid tumors and multiple myeloma. In pediatric acute myeloid leukemia (AML), IL-6–induced STAT3 signaling frequently becomes stronger at relapse, and increases in IL-6–induced STAT3 activity are associated with inferior survival after relapse. These findings suggested that the IL-6–induced STAT3 pathway may promote chemotherapy resistance and disease progression. Thus, we investigated the dysregulation of IL-6 levels in the bone marrow niche in pediatric patients with AML and the association between IL-6 levels and outcome. We measured levels of over 40 cytokines and growth factors in plasma from diagnostic bone marrow aspirates of 45 pediatric AML patients and 7 healthy sibling controls. Of the measured cytokines, only IL-6 levels were associated with event-free survival. Importantly, the effect of elevated IL-6 was most striking among children classified as having a low risk of relapse. In these patients, 5-year event-free survival was 82.5% ± 11% for patients with low IL-6 levels at diagnosis (n = 14) compared with 17.3% ± 11% for patients with elevated IL-6 (n = 13, log-rank P = .0003). In vitro, exogenous IL-6 reduced mitoxantrone-induced apoptosis in cell lines and primary pediatric AML samples. These results suggest that IL-6 levels at diagnosis could be used to help identify children at high risk of relapse, particularly those who are otherwise classified as low risk by current algorithms. Moreover, the IL-6 pathway could represent a target for overcoming environment-mediated chemotherapy resistance.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox